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ORIGINAL RESEARCH

Invasive Hemodynamic Monitoring in
Cardiogenic Shock Is Associated With
Lower In-Hospital Mortality
Mohammed Osman , MD; Moinuddin Syed, MD; Brijesh Patel, DO; Muhammad Bilal Munir , MD;
Babikir Kheiri , MD, MSc; Marco Caccamo , DO; George Sokos, DO; Sudarshan Balla , MD;
Mir Babar Basir, DO; Navin K. Kapur , MD; Mamas A. Mamas , MD; Christopher M. Bianco, DO
BACKGROUND: There is increasing utilization of cardiogenic shock treatment algorithms. The cornerstone of these algorithms is
the use of invasive hemodynamic monitoring (IHM). We sought to compare the in-hospital outcomes in patients who received
IHM versus no IHM in a real-world contemporary database.
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METHODS AND RESULTS: Patients with cardiogenic shock admitted during October 1, 2015 to December 31, 2018, were identified from the National Inpatient Sample. Among this group, we compared the outcomes among patients who received IHM
versus no IHM. The primary end point was in-hospital mortality. Secondary end points included vascular complications, major
bleeding, need for renal replacement therapy, length of stay, cost of hospitalization, and rate of utilization of left ventricular
assist devices and heart transplantation. Propensity score matching was used for covariate adjustment. A total of 394 635
(IHM=62 565; no IHM=332 070) patients were included. After propensity score matching, 2 well-matched groups were compared (IHM=62 220; no IHM=62 220). The IHM group had lower in-hospital mortality (24.1% versus 30.6%, P<0.01), higher
percentages of left ventricular assist devices (4.4% versus 1.3%, P<0.01) and heart transplantation (1.3% versus 0.7%, P<0.01)
utilization, longer length of hospitalization and higher costs. There was no difference between the 2 groups in terms of vascular
complications, major bleeding, and the need for renal replacement therapy.
CONCLUSIONS: Among patients with cardiogenic shock, the use of IHM is associated with a reduction in in-hospital mortality
and increased utilization of advanced heart failure therapies. Due to the observational nature of the current study, the results
should be considered hypothesis-generating, and future prospective studies confirming these findings are needed.
Key Words: cardiogenic shock ■ invasive hemodynamic ■ pulmonary arterial catheter ■ Swan-Ganz catheter

C

ardiogenic shock (CS) is a life-threatening condition characterized by acute end-
organ hypoperfusion due to inadequate cardiac output,
resulting in multi-organ failure culminating in death.1-4
Contemporary data from specialized cardiogenic
shock centers shows that early recognition and algorithmic approaches for managing CS with the rapid
deployment of MCS are associated with a reduction in mortality.5-7 Invasive hemodynamic monitoring
(IHM) is the cornerstone of such treatment algorithms,

emphasizing early diagnosis and phenotyping of
CS. The ESCAPE (Evaluation Study of Congestive
Heart Failure and Pulmonary Artery Catheterization
Effectiveness) trial reported a lack of benefit with IHM.
Since then, there has been a decreasing trend in IHM
use among patients admitted with congestive heart
failure and cardiogenic shock.8-13 It is essential to highlight that studies evaluating the role of IHM; including the ESCAPE trial, excluded patients with CS and
were conducted before the current era of advances in
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CLINICAL PERSPECTIVE
What Is New?

• Among patients with cardiogenic shock, the
use of invasive hemodynamic monitoring is associated with a reduction in in-hospital mortality
and increased utilization of durable left ventricular assist devices and heart transplantation.

What Are the Clinical Implications?

• The use of invasive hemodynamic data to guide
the care of patients with cardiogenic shock is
associated with reduced in-hospital mortality.
• Treatment protocols relying on invasive hemodynamic data in patients with cardiogenic shock
should be further studied in randomized clinical
trials.

Nonstandard Abbreviations and Acronyms
AHRQ
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CS
IHM
NIS

Agency for Healthcare Research and
Quality
cardiogenic shock
invasive hemodynamic monitoring
National Inpatient Sample

MCS.11,14,15 Using a large nationally representative sample of patients with CS, we sought to determine the
impact of IHM use, as well as the timing of use, on clinical outcomes including in-
hospital mortality among
patients admitted with CS.

METHODS
Study Data
The study was derived from the National Inpatient
Sample (NIS), from October 1, 2015 to December 31,
2018. The NIS database is part of the Healthcare Cost
and Utilization Project (HCUP) databases and is sponsored by the Agency for Healthcare Research and
Quality (AHRQ).16 The NIS is the largest publicly available all-
payer administrative claims-
based database
and contains patient discharges from 1000 hospitals
in 45 states. It has clinical and resource utilization information on more than 7 million discharges annually.
Weighted, it represents more than 35 million hospitalizations nationally on an annual basis. These data are
stratified to represent 20% of US inpatient hospitalizations across different hospital and geographic regions
(random sample).16 Institutional review board approval
and informed consent were not required for this study,

given the NIS database’s de-identified nature and public availability. Because of the sensitive nature of the
data collected for this study, requests to access the
data set from qualified researchers trained in human
subject confidentiality protocols may be sent to the
Healthcare Cost and Utilization Project at https://www.
hcup-us.ahrq.gov/tech_assist/centdist.jsp.

Study Population
Adult patients (≥18 years) admitted with CS during
October 1, 2015 to December 31, 2018, were identified in the NIS using the International Classification
of Disease, Tenth Revision Clinical Modification Code
(ICD-10-CM) R570, which was applied to all the diagnoses variables provided by the dataset. We then identified patients who underwent IHM during the same
admission using the ICD-10 procedure codes (ICD-
10-
PCS) 4A1239Z, 4A0239Z, 4A023N6, 4A023N8,
4A033J3, 4A033B3, 4A03353, 4A13353, 4A133B3,
4A133J3, and 02HP32Z, which codes for measurement, monitoring, or insertion of monitoring device to
check cardiac output or pulmonary artery hemodynamics. Similar methods were used in previous studies
to identify patients who received IHM.10,12,17 The complete list of the codes used in the current analysis is
provided in Table S1.
We excluded patients who underwent only left
heart catheterization without accompanying right heart
catheterization. Furthermore, we excluded the following patients: (1) patients with missing mortality, age, or
sex data, (2) patients who were younger than 18 years,
(3) patients who received concomitant cardiac surgery
(coronary artery bypass grafting or valve surgery), transcatheter aortic valve replacement, mitral clip or catheter ablation during the same hospitalization, (4) patients
who died on the day of admission, (5) patients with the
diagnosis of primary pulmonary hypertension, (6) patients who were admitted electively to the hospital, and
(7) patients who received the IHM after or on the same
day of receiving durable left ventricular assist devices
(LVADs) or heart transplantation (HT).
We have conducted several analyses on the included population as follows: (1) a primary analysis
comparing the in-hospital outcomes among patients
who received IHM versus no IHM, (2) a secondary
analysis assessing the impact of the timing of IHM
on in-hospital outcomes; this was performed by constructing 3 different matched cohorts to compare the
outcomes among patients who received early IHM
(eIHM) (within the first 24 hours) versus delayed IHM
dIHM (after the first 24 hours and up to a week) and versus matched controls (no IHM), (3) sensitivity analysis
by stratifying the primary outcome based on the type
of the CS (acute myocardial infarction-CS [AMIC-CS or
Non-AMI-CS]), (4) sensitivity analysis by restricting the
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included cohort to patients who received an indwelling
pulmonary artery catheter (PAC). Following methods
used in previous studies, the PAC cohort was isolated
by identifying patients who received codes for monitoring or insertion of monitoring device to check cardiac output or pulmonary artery hemodynamics,10 and
(5) sensitivity analysis by excluding patients who died
within 72 hours of admission. Additionally, as previous
studies suggested disparity in the management and
outcomes of CS, we have conducted several subgroups analyses for the primary outcome based on
demographic groups to detect heterogeneity of the
treatment effect among the different subgroups as follows: (1) a subgroup analysis stratified by sex, (2) a subgroup analysis stratified by race, and (3) a subgroup
analysis stratified by age.18,19
Additionally, due to the study’s observational nature,
we estimated the strength of unmeasured confounding
using the E-Value methodology of VanderWheel and
Ding.20 This method estimates the minimum strength
of the association that would be required between an
unmeasured confounder and both exposure (IHM) and
outcome (in-hospital mortality) to overcome the statistically significant effect observed in a study where
residual confounding is a potential problem. The calculation was derived from the odds ratio obtained from
the analysis after applying propensity score matching.
Moreover, we used falsification end points analysis to
further guard against residual confounders. In falsification analysis, one or more end points thought to
be unrelated to the exposure of interest (IHM) are prespecified. The association between the exposure and
outcome is tested after adjustment for confounders.
The presence of any spurious association between
the exposure and outcome suggests that the current
analysis is prone to bias from unmeasured confounders.21,22 For the present study, we used 2 separate
falsification end points, including catheter-associated
urinary tract infection and sacral decubitus ulcers.

Study End Points
The primary end point of this study was in-hospital
mortality. Secondary end points included vascular complications, major bleeding (defined as post-
procedural bleeding requiring blood transfusion), need
for renal replacement therapy (RRT), resources utilization surrogates (length of stay and cost of hospitalization), and utilization of advanced heart failure therapies
(LVADs and HT). The need for RRT was considered to
be present after excluding patients who are dialysis-
dependent to isolate patients with a new requirement
for RRT during the hospitalization. We also reported
the percentage of patients with a concomitant code
for bloodstream infection in the 2 groups as a safety
end point.

Invasive Hemodynamic in Cardiogenic Shock

Statistical Analysis
All variables are expressed as weighted national estimates. This was done following the survey analysis
method by incorporating the (HOSP_NIS) as a clustering variable and accounting for the different strata in
the NIS design using the (NIS_STRATUM) as recommended in the AHRQ methods series.16 Categorical
variables were expressed as count (percentage)
and compared using the Scott-Rao Chi-square test.
Continuous variables were expressed as median (interquartile range) and compared using the Wilcoxon
rank-sum test.
Moreover, for the primary analysis, a propensity
score-
matching (PSM) Model was calculated using
multivariate logistic regression to derive 2 matched
groups for comparative outcomes analyses (IHM versus no IHM). A nearest-
neighbor 1:1 variable ratio,
parallel, balanced propensity-
matching model was
applied using a caliper width of 0.01. The variables included in the PSM model included demographics (age,
sex, and race), comorbidities (hypertension, diabetes
mellitus, chronic kidney disease, chronic heart failure,
peripheral vascular disease, chronic lung disease, cancer, chronic liver disease, coagulopathy, prior stroke,
smoking, and obesity), clinical factors (AMI-CS or need
for mechanical ventilation or percutaneous coronary
intervention), MCS use, and hospital characteristics
(hospital bed size and teaching status). Moreover, the
same PSM model was used to derive 3 more comparative cohorts to compare the outcomes among (eIHM
versus dIHM), (eIHM versus no IHM), and (dIHM versus
no IHM).
Additionally, multivariable risk adjustments using
several models derived from generalized structured
equation modeling to account for the clustering of data
within different hospitals were used to assess the impact of various confounding factors on the primary end
point as follows: Model (1) adjusted for demographic
and clinical comorbidities; Model (2) adjusted for demographic, comorbidities and clinical factors; Model
(3) adjusted for demographic, clinical comorbidities,
clinical presentation on admission, and hospital characteristics; Model (4) adjusted for demographic, clinical
comorbidities, clinical presentation on admission, hospital characteristics, and MCS use; and Model (5) adjusted for demographic, clinical comorbidities, clinical
presentation on admission, hospital characteristics,
MCS use, and advanced heart failure therapies. Within
model 5, we tested for interaction between IHM and
advanced heart failure therapies. We used the cost-to-
charge ratio files provided by the HCUP to convert the
hospital charges to more accurate hospital costs for
cost calculations. A P value of <0.05 was considered
statistically significant. For statistical analyses, we used
the statistical package for social science (SPSS) version
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26 (IBM Corp) and R, version 3.5 for the main analysis and propensity matching, respectively. Additionally,
we used Stata Statistical Software: Release 15 (Stata-
Corp. 2017) to build the models for adjusted analysis
using generalized structured equation modeling.

RESULTS
A total of 394 635 (IHM=62 565; no IHM=332 070)
patients qualified to be included in the current analysis. The flow chart of the study is shown in Figure 1.
Comparing patients who underwent IHM to no IHM,
IHM patients were younger (64 years [IQR 55–72] versus
68 years [IQR 58–78], P<0.01), less likely to be females
(33.1% versus 38.6%, P<0.01), had higher prevalence
of chronic heart failure (36.3% versus 27.9%, P<0.01),
chronic kidney disease (39.2% versus 36.8% P<0.01),
obesity (19.4% versus 17.7%, P<0.01), and coagulopathy (25.5% versus 22.7%; P<0.01). Moreover, the IHM
had higher utilization of percutaneous coronary interventions (PCI) (23.9% versus 18.6%; P<0.01). On the
other hand, IHM patients had lower prevalence of metastatic cancer (1% versus 2.3%, P<0.01), chronic lung

Invasive Hemodynamic in Cardiogenic Shock

disease (24.2% versus 27.6%, P<0.01), and prior stroke
(8.3% versus 9.2%, P<0.01). A detailed description of
the baseline characteristics is shown in (Table 1).
After PSM, 2 well-matched IHM and no IHM groups
were compared (n=62 220 for each group) (Table 2).
After PSM, standardized mean differences were reduced to <10% for all the covariates, indicating a balanced population. The variables used in the PSM and
the result of the PSM are shown in Figure 2. The IHM
group showed lower in-hospital mortality (24.1% versus
30.6%, P<0.01, OR 0.7 [95% CI 0.67–0.74]) with higher
utilization of LVADs (4.4% versus 1.3%, P<0.01) and HT
(1.3% versus 0.7%, P<0.01) longer length of hospitalization (median=11 versus 7 days, P<0.01) and higher costs
(median=45 511$ versus 31 290, P<0.01). There was no
difference between the 2 groups in terms of vascular
complications, major bleeding, and the need for RRT
(Table 2). There was a consistent reduction in in-hospital
mortality in all the subgroups with no detected heterogeneity (Figure 3). Moreover, in the sensitivity analysis,
the association of IHM with reduced mortality persisted
in both AMI-
CS (IHM=30.8% versus no IHM=34%,
P<0.01) and non-
AMI-
CS groups (IHM=19.4% versus

Downloaded from http://ahajournals.org by on October 18, 2021
Figure 1. Flow chart of the study.
CS indicates cardiogenic shock; IHM, invasive hemodynamic monitoring; LVAD, left ventricular assist devices; TMVR, transcatheter
mitral valve repair; and TAVR, transcatheter aortic valve replacement.
J Am Heart Assoc. 2021;10:e021808. DOI: 10.1161/JAHA.121.0218084
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64 (55–72)

33.1

Age, median (25th–75th IQR), y

Female

17.7
8.8
11.9

14.9

8.4

11

Black

Hispanic

22.7
6.5
27.6
17.7

1

25.5

6.5

24.2

Metastatic cancer

Coagulopathy

Chronic liver disease

Chronic lung disease

27.9

IABP

87.5

Urban teaching

75

20.5

77

18.9

4.1

61.4

25.8

12.9

13.5

15.5

2.2

19.5

47.6

22.4

20.1

16.3

9

17.9

27.1

6.5

23.1

2.1

37.2

29.3

12.9

73.7

39.5

11.1

8.7

15.3

64.8

37.7

67 (58–77)

Total (n=394 635)

0.39

0.37

0.27

0.06

0.09

0.1

−0.21

−0.05

−0.04

−0.05

−0.03

0.04

−0.09

<0.01

0.07

−0.14

0.07

0.18

−0.03

0.02

0.02

0.04

−0.12

−0.24

SMD

73.9

18.9

7.2

73.9

18.9

7.2

23.3

17.2

3.6

23.8

39.9

21.9

19.9

15.2

8.3

19.4

24.3

6.4

25.4

1

39.1

36

12.6

74.4

40.3

11.8

8..4

17.7

62

33.1

64 (55–73)

IHM (n=62 220)

Matched Cohorts

73.6

19.9

6.5

73.6

19.9

6.5

22.7

18

3.5

24

39.8

22.2

20.3

15.1

8.1

19.9

24.9

6.1

25.7

1.1

38.4

35.7

12.4

75

40.8

11.8

9.4

16.2

62.7

32.5

64 (56–75)

No IHM (n=62 220)

73.7

19.4

6.9

73.7

19.4

6.9

23

17.6

3.5

23.9

39.8

22

20.1

15.2

8.2

19.6

24.6

6.3

25.6

1

38.7

35.9

12.5

74.7

40.5

11.8

8.9

16.9

62.4

32.8

64 (55–74)

Total (n=12 440)

0.03

<0.01

<0.01

<0.01

<0.01

−0.01

0.02

−0.01

−0.02

<0.01

0.01

−0.02

<0.01

<0.01

<0.01

<0.01

<0.01

<0.01

<0.01

<0.01

<0.01

<0.01

<0.01

<0.01

<0.01

<0.01

<0.01

<0.01

SMD

ECMO, extra-corporal membrane oxygenation; IABP indicates intra-aortic balloon pump; IHM, invasive hemodynamic monitoring; IQR, inter-quartile range; SMD, standardized mean difference; NSTEMI, non–ST-
segment–elevationmyocardial infarction; PCI, percutaneous coronary intervantion; and STEMI, non–ST-segment–elevationmyocardial infarction.
*Other includes Asian or Pacific Islander, Native American and unknown race.

1.9

10.6

Rural non-teaching

Urban non-teaching

4.5

59

74

Hospital teaching status

Large

27.1

7.2

18.8

Small

13.9

11.6

15.2

2

16.5

Medium

Hospital bed size

17.3

23.7

Impella ®

18.6

23.9

3.7

PCI

22.5
49.1

21.9

39.7

NSTEMI

Mechanical ventilation

ECMO

20.2

15.2

19.8

Smoking

STEMI

9.2

19.4

8.3

Obesity

Prior stroke

2.3

36.8

36.3

39.2

Chronic heart failure

73.6
12.9

74.4

12.6

Hypertension

Peripheral vascular disease

Chronic kidney disease

39.3

40.3

Diabetes mellitus

Other*

65.3

38.6

68 (58–78)

No IHM (n=332 070)

62

White

Race

IHM (n=62 565)

Variables (%)

Unmatched Cohorts

Table 1. Baseline Characteristics of Patients Included in the Analysis Before and After Propensity Score Matching
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0.9

4.9

9.4

0.6

Major bleeding

RRT

Central line
associated
bloodstream
infections

1.4

Heart
transplantation

46 553
(25 685–87 062)

Cost of
hospitalization
median $
(25th−75th IQR)
28 117 (14 848–51 918)

7 (3 − 13)

0.3

0.6

0.4

8.7

4.9

0.7

35.8

No IHM (n=332 070)

30 607
(16 129–57 055)

7 (3 − 14)

0.5

1.2

0.4

8.8

4.9

0.7

34

Total (n=394 635)

<0.01

<0.01

<0.01

<0.01

<0.01

0.02

0.77

0.01

<0.01

P value

45 511
(25 809–81 470)

11 (6 − 18)

1.3

4.4

0.6

9.4

4.8

0.9

24.1

IHM (n=62 220)

Matched cohorts

31 290
(16 364–58 325)

7 (4 − 14)

0.7

1.3

0.4

9

5.4

0.9

30.6

No IHM (n=62 220)

IHM indicates invasive hemodynamic monitoring; IQR indicates inter-quartile range; LVAD, left ventricular assist devices; and RRT, renal replacement therapy.

11 (6 − 19)

Length of
hospitalization
median days
(25th–75th IQR)

Resources utilization

4.5

LVAD

Utilization of advanced heart failure therapy

24.1

Vascular
complications

IHM (n=62 565)

Death

In-hospital outcomes

Variables no. (%)

Unmatched cohorts

Table 2. In-Hospital Outcomes of Patients Included in the Analysis Before and After Propensity Score Matching

38 098
(20 579–69 981)

9 (5 − 16)

1

2.8

0.5

9.2

5.1

0.9

27.4

Total (n=12 440)

<0.01

<0.01

<0.01

<0.01

<0.01

0.24

0.06

0.89

<0.01

P value

Osman et al
Invasive Hemodynamic in Cardiogenic Shock

J Am Heart Assoc. 2021;10:e021808. DOI: 10.1161/JAHA.121.0218086

Osman et al

Invasive Hemodynamic in Cardiogenic Shock

Downloaded from http://ahajournals.org by on October 18, 2021
Figure 2. Dot plot showing covariates balance before and after the propensity matching.
AMI indicates acute myocardial infarction; MCS, mechanical circulatory support; and PCI, percutaneous
coronary intervention. *Overall balance represents the average standardized mean difference for all the
covariates before and after the propensity score matching.
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Figure 3. Result from the subgroup analysis.
IHM indicates invasive hemodynamic monitoring; and OR, odds ratio.
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no IHM 37.4%, P<0.01). Additionally, in the sensitivity
analyses in which patients who died within 72 hours
were excluded or the analysis was restricted to the PAC
cohort, the association of IHM with reduced in-hospital
mortality remained statistically significant (IHM=18.1%,
no IHM=20%, P<0.01) and (PAC=28%, no PAC=31%,
P=0.02), respectively. The IHM group had a higher percentage of bloodstream infection than the no IHM group
(0.6% versus 0.4%, P<0.01).

In the risk-adjusted analyses, the use of IHM continued to be associated with lower in-hospital mortality.
In model 1, adjusting for demographics and comorbidities, the utilization of IHM was associated with reduced in-hospital mortality (adjusted odds ratio [aOR]
0.60, 95% CI 0.57–0.63). The results were consistent
in model 2, which also adjusted for clinical factors
present on admission (aOR 0.70, 95% CI 0.65–0.72),
in model 3, which additionally adjusted for hospital

Figure 4. Results of the multivariable risk adjustment analysis
IHM indicates invasive hemodynamic monitoring; and OR, odds ratio.

J Am Heart Assoc. 2021;10:e021808. DOI: 10.1161/JAHA.121.0218088
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characteristics (aOR 0.67, 95% CI 0.63–0.70), in model
4, which additionally adjusted for temporary MCS (aOR
0.68, 95% CI 0.64–0.72), and in model 5, which was
the most robust Model which included all the previously mentioned covariates and additionally adjusted
for the use of advanced heart failure therapy (aOR
0.69, 95% CI 0.66–0.73) (Figure 4). The utilization of
IHM was associated with reduced in-hospital mortality
regardless of the utilization of advanced heart failure
therapies (P for interaction=0.86).
In an additional analysis comparing the timing
of IHM, both early and delayed IHM were associated with better in-hospital mortality compared to no
IHM (eIHM=26% versus no IHM=30%, P<0.01) and
(dIHM=21.5% versus no IHM=29%, P<0.01), respectively. However, after PSM comparing early versus
delayed IHM, there was no difference between the 2
in terms of in-hospital mortality (eIHM=22.2% versus
dIHM=22.7%, P=0.61) (Table 3).
To quantify the strength of any possible unmeasured confounder, we calculated the E-Value following the methodology of VanderWheel and Ding for
the primary outcome of in-hospital mortality.20 The
E-Value (Odds Ratio Scale) for in-hospital mortality
was 1.7. Thus, our observed reduction in in-hospital
mortality among patients who were admitted with CS
and treated with IHM could potentially be explained
by an unmeasured confounder that was associated
with both the use of IHM and reduction of in-hospital

mortality by an OR of 1.7, but weaker confounders
could not explain this association. Moreover, while
the primary analysis showed an association between
IHM use and reduced in-
hospital mortality, there
was no statistical evidence of a spurious association between IHM and any of the falsification end
points used in the current study as follow: catheter-
associated urinary tract infection (IHM=0.3%, no
IHM=0.3%, P=0.9) and sacral ulcers (IHM=2.62%,
no IHM=2.6%, P=0.1).

DISCUSSION
This is the largest contemporary study, using a nationally representative sample of patients with CS, assessing the impact of IHM on clinical outcomes. There are
several significant findings from our study as follow: (1)
Among all hospitalized patients with CS, IHM is associated with a significant reduction in in-hospital mortality,
(2) the use of IHM is associated with higher utilization
of advanced heart failure therapies (LVADs and HT),
(3) IHM is associated with reduced mortality in CS for
both AMI-CS and non-AMI-CS, (4) the association between use of IHM and reduced in-hospital mortality
was consistent among the different subgroups (males
versus females, White versus non-White, and old versus young patients) (Figure 5), (5) the IHM group was
associated with longer length of stay and higher cost
compared to the no IHM group, and (6) the IHM group

Table 3. In-Hospital Outcomes Based on Timing of IHM of the Patients Included in Analysis Before and After Propensity
Score Matching
Unmatched cohorts

Matched cohorts

Early IHM
(n=30 430)

Late IHM
(n=21 145)

Total
(n=51 575)

P Value

Early IHM
(n=17 735)

Late IHM
(n=17 735)

Total (n=35 470)

P Value

Death

26.9

21.5

24.7

<0.01

22.2

22.7

22.4

0.61

RRT

8

9.3

8.5

<0.01

8.6

9.2

8.9

0.33

Heart transplant

0.6

1.3

0.9

<0.01

1

1.3

1.1

0.17

LVADs

3.2

5.2

4

<0.01

4.6

4.8

4.7

0.77

Early IHM
(n=30 430)

No IHM
(n=332 070)

Total
(n=362 500)

P Value

Early IHM
(n=30 340)

No IHM
(n=30 340)

Total (n=60 680)

P Value

Death

26.9

35.4

34.7

<0.01

26

30

28

<0.01

RRT

8

8.9

8.8

0.044

8

8.5

8.2

0.36

Heart transplant

0.6

0.5

0.5

0.17

0.6

0.9

0.7

0.052

LVADs

3.2

0.8

1

<0.01

3.2

1.3

2.2

<0.01

Late IHM
(n=21 145)

No IHM
(n=332 070)

Total
(n=353 215)

P Value

Late IHM
(n=21 025)

No IHM
(n=21 025)

Total (n=42 050)

P Value

Death

22

35

34.5

<0.01

21.5

29

25.3

<0.01

RRT

9.3

8.9

8.9

0.34

9.3

10

9.6

0.28

Heart transplant

1.3

0.5

0.5

<0.01

1.2

1.3

1.2

0.63

LVADs

5.2

0.8

1.1

<0.01

5.1

2.3

3.7

<0.01

Variables no. (%)
In-hospital outcomes

IHM indicates invasive hemodynamic monitoring; LVAD, left ventricular assist devices; and RRT, renal replacement therapy.
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Figure 5. Summary of the main findings from the study.
Arrows indicate reduction in in-hospital mortality and higher left ventricular assist devices (LVADS) utilization and heart transplant
utilization.

had a higher percentage of concomitant bloodstream
infections compared to the no IHM group.
Literature supporting hemodynamic monitoring in CS
dates as far back as the 1970s.23 Data from the SHOCK
registry from ≈2 decades back showed that IHM in CS
provides prognostic information that predicts mortality.24 Contemporary literature from the cardiogenic
shock working group indicates that IHM can be used
for phenotyping CS (left ventricular shock, right ventricular shock, or biventricular shock) and guide initial
triaging, as well as directing timely escalation of pharmacologic or mechanical support in CS.25-28 A recent
study utilized NIS data from 2000 to 2014; the authors
reported a 75% reduction in IHM over the study period
and found no reduction in in-hospital mortality in the
IHM group.10 The differences in the findings between
our study and the previous analysis can be explained
by several means. First, our analysis included more
contemporary data extending from October 2015
until December 2018. During the study period, there
have been advances in the care of patients with CS
after adopting CS treatment algorithms on a national
scale.5-7 Secondly, the previous study included only

patients with AMI-CS. In contrast, in the current analysis, we included all CS types and performed a sensitivity analysis based on CS type. In another study,
Hernandez et al specifically studied the role of IHM
among patients admitted with acute decompensated
heart failure (ADHF). They showed higher mortality
with the use of IHM in patients with ADHF without CS.8
Among patients with CS, IHM’s use was associated
with lower mortality, consistent with our findings.8
Moreover, smaller studies from specialized CS centers showed that the use of IHM among patients with
AMI-CS is associated with improved survival.5,6
Although an association was observed between IHM
use in CS and reduced mortality, this does not imply causality. The IHM-derived invasive hemodynamic monitoring provides essential diagnostic and prognostic data.
It requires that this data be interpreted accurately and
coupled with an expeditious and appropriate treatment
strategy to improve clinical outcomes.2,29 Sionis et al, in
a study from a European multi-center registry of patients
with CS, showed that patients who received IHM were
managed more aggressively, including more frequent
use of vasopressors, inotropes, and mechanical assist

J Am Heart Assoc. 2021;10:e021808. DOI: 10.1161/JAHA.121.02180810

Osman et al

Downloaded from http://ahajournals.org by on October 18, 2021

devices.30 We hypothesize that improvement in survival
with IHM use in CS is due to earlier recognition, phenotyping, and appropriate triaging of patients with CS. This
approach encourages tailored therapeutic interventions
directed at the preservation of end-organ function and
myocardial recovery. Using this strategy of IHM coupled
with appropriate, timely use of MCS, specialized CS
centers have shown a dramatic reduction in mortality in
CS.5,6,7,25 Moreover, consensus documents have also endorsed the routine early use of IHM among all patients
with CS.2,29
Our analysis showed an association between IHM
use in CS and higher LVAD and HT utilization. In contemporary practice, patients with CS are often stabilized with temporary MCS, and appropriate candidates
are bridged to definitive advanced therapies including
durable LVAD or HT.31 Early recognition of evolving CS,
allowing for interventions aimed to preserve or improve
failing end-
organ function, are paramount in maintaining physiologic candidacy for definitive advanced
therapies. Without prompt interventions, multi-organ
failure may ensue, rendering patients with CS no longer candidates for advanced therapies. Furthermore,
IHM informed CS phenotyping helps guide selective
bridging strategies to definitive therapy.31 For instance,
an essential benefit of IHM is early recognition of biventricular failure, which is often under-
recognized and
may warrant consideration of bi-ventricular support.26
It is important to note that the current analysis was
limited to only 3 months of data reflecting the current
United Network for Organ Sharing (UNOS) HT allocation scheme (implemented in September 2018). The
updated UNOS allocation scheme has shifted priority
from patients supported with durable devices to those
with temporary mechanical support. A future study incorporating more data in the updated UNOS HT allocation scheme will be of interest.
In the contemporary era of robust MCS availability, early recognition of CS and IHM-guided therapy is
critical to prevent progression from hemodynamic insufficiency to profound hemo-metabolic derangement,
which is invariably associated with higher mortality.32
Hemodynamic data provided by IHM can confirm
evolving CS and provide vital information used to customize a therapeutic strategy based on severity and
phenotype. Moreover, IHM provides real-
time feedback about adequacy of therapy and to determine if
escalation in pharmacologic or mechanical support is
warranted.26,29,32

Study Limitations
Our study has several limitations that need to be considered when interpreting the result from the current
analysis. First, this is a retrospective observational study
that is prone to unmeasured confounding variables.

Invasive Hemodynamic in Cardiogenic Shock

However, we addressed the unmeasured confounding risk by using PSM, conducting several sensitivity
analyses, and calculating the strength of the unmeasured confounder needed to change the study results
(E-Value). Second, this analysis uses billing codes to
identify procedures and outcomes, and those are
subject to under-or over-coding. However, we used a
hard clinical end point for the primary outcome (death),
which is less prone to coding errors. Third, due to the
dataset’s inherent limitation, we do not have hemodynamic, metabolic, or clinical data, which is vital in staging cardiogenic shock. There is emerging data that the
efficacy of various therapeutic interventions depends
on the stage of CS.28 Fourth, the current analysis is
prone to survivor treatment selection bias. It is likely
that the sickest patients in extremis (Stage E CS), who
have the highest mortality, receive fewer diagnostic
maneuvers like IHM. However, we have accounted for
that by excluding the patients with severe cardiogenic
shock who died within 24 hours of admission, thus
increasing the validity of our study. Furthermore, we
performed an additional sensitivity analysis excluding
patients who died within 72 hours from admission to
reduce the chance of survivor treatment bias. Fifth, the
NIS database does not provide data on the hospital
unit (medical intensive care versus cardiac intensive
care or a step-down unit) and hence could not control for that in the current analysis. The IHM group may
be a marker for admission to cardiac intensive care
units, which are linked to better outcomes, including
in-hospital mortality among patients with CS.33 Sixth,
due to the NIS sampling change after the year 2011, it
is no longer possible to conduct hospital volume analysis. Consequently, we were not able to adjust for that in
the current analysis. However, we have used hospital
bed size and teaching status as surrogates for hospital
volume. Seventh, although we report an association
between IHM and utilization of advanced heart failure
therapies, it is well known that right heart catheterization is a crucial part of the workup for patients who
are undergoing elective HT or LVAD. However, we excluded patients who were admitted electively or patients who received the IHM after or on the same day
of receiving LVAD or HT. It is essential to note that the
current observational nature of the analysis makes it
hypothesis-generating. The conclusions from the current analysis draw attention to the need for further prospective studies to confirm the association between
IHM use and improved in-
hospital mortality among
patients with CS.

CONCLUSIONS
Among patients admitted with CS, we observed an
association between IHM utilization and reduced in-
hospital mortality. Moreover, IHM was associated with
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higher utilization of advanced heart failure therapies
(LVADs and HT). The findings suggest that a hemodynamic guided approach to CS management may
improve survival. Due to the observational nature of
the current study, the results should be considered
hypothesis-generating, and future prospective studies
confirming these findings are needed.
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Table S1. International classification of disease-10th
modification codes Used in the Analysis
Disease/
Complication
ACS
Comorbidities
Percutaneous coronary
intervention

Vascular complications
Downloaded from http://ahajournals.org by on October 18, 2021

Post-procedural bleeding

Blood transfusion

Renal Replacement
Therapy
Left Ventricular Assist
Device
Heart Transplant
ECMO
Impella ® pumps
IABP

Codes
I210, I2101, I2102 , I2109, I211 , I2111 , I2119 , I212 , I2121 , I2129 , I213 , I214 , I219

Elixhauser Comorbidity Codes
0270346,027034Z,0270356,027035Z,0270366,027036Z,0270376,027037Z,02703D
6,02703DZ,0272346,027234Z,0272356,027235Z,027236Z,02703EZ,0272366,0272
376,027237Z,02723D6,02723DZ,02703E6,02703F6,02703FZ,02703G6,02703GZ,0
2703Z6,02703ZZ,0270446,027044Z,0270456,02723E6,02723EZ,02723F6,02723F
Z,02723G6,0272446,027045Z,0270466,027046Z,0270476,027047Z,02704D6,0272
3GZ,02723Z6,02723ZZ,027244Z,0272456,02704DZ,02704E6,02704EZ,02704F6,0
27245Z,0272466,027246Z,0272476,027247Z,027247Z,02724D6,02724DZ,02724E
6,02724EZ,02724F6,02704FZ,02704G6,02704GZ,0271346,027134Z,0271356,0271
35Z,0271366,027136Z,02704Z6,02704ZZ,02724FZ,02724G6,02724GZ,02724Z6,0
2724ZZ,0273346,027334Z,0273356,027335Z,0273366,027336Z,0271376,027137Z,
02713D6,02713DZ,02713E6,02713EZ,02713F6,02713FZ,02713G6,02713GZ,0271
3Z6,0273376,027337Z,02733D6,02733DZ,02733E6,02733EZ,02733F6,02733FZ,0
2733G6,02733GZ,02733Z6,02713ZZ,0271446,027144Z,0271456,027145Z,027146
6,027146Z,0271476,027147Z,02733ZZ,0273446,027344Z,0273456,027345Z,02734
66,027346Z,0273476,027347Z,02714D6,02714DZ,02714E6,02714EZ,02714F6,027
14FZ,02714G6,02714GZ,02714ZZ,02714Z6,02734D6,02734DZ,02734E6,02734EZ
,02734F6,02734FZ,02734G6,02734GZ,02734Z6,02734ZZ.
S36899A,T81718A,T81719A,T8172XA,T81710A,T81711A,T801XXA,I770,S2500
XA,S2501XA,S2502XA,S2509XA,S3500XA,S3501XA,S3502XA,S3509XA,S750
11A,S75012A,S75019A,S75021A,S75022A,S75029A,S75099A,I97410,I97411,I97
418,I9742,I97610,I97611,I97618,I97620,L7602,L7622,M96811,M96831,I9751,I97
52,L7612,M96821,T8171,T8172,S25499A,S3559XA,S45001A,S45099A,S75001A,
S75199A,S85001A,S85599A
I97410,I97418,I97610,I97618,I97630,I9742,I97620,I97410,I97411,I97418,I9742,I9
7610,I97621,I97630,I97640,I97618,I97621,L7602,L7622,M9681,M9683,M96811,
K661,D62
30233M*,30233N*,30233P*,30233R*,30233T*,30233V*,30233W*
,30233W*,30233W*,30233W*,30240H*,30240J*,30240K*,30240L*
,30240M*,30240N*,30240P*,30240R*,30240T*,30240V*,30240W*
,30240T*,30243H*,30243K*,30243L*,30243H*,30243M*,30243N*
,30243P*,30243R*,30243T*,30243V*,30243W* ,3028***
5A1D70Z, 5A1D80Z, 5A1D90Z, 5A1D60Z, 5A1D00Z
02HA0QZ
02YA0Z0, 02YA0Z1
5A1522F, 5A1522G, 5A15A2F, 5A15A2G, 5A15223
5A0221D, 5A0211D
5A02210

